Search research articles
Contact Us
Filters
Showing results (231-240 of 256) with videos related to
Page
of 26
Sort By:
Clinical Pharmacology and Therapeutics
|
August 4, 2004
Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states
Kyung-Sang Yu, Joo-Youn Cho, In-Jin Jang, et al.
Pharmacogenomics
|
September 26, 2025
CYP2D6 genotyping in a Korean cohort: comparative analysis with Asian, Caucasian, and African populations
Tak Don Kim, Jung-Sook Kwak, Jae-Gook Shin, et al.
Chemico-Biological Interactions
|
March 3, 2023
Systems-level multi-omics characterization provides novel molecular insights into indomethacin toxicity
Nguyen Thi Hai Yen, Jung-Hwa Oh, Nguyen Thi Van Anh, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
|
January 12, 2022
Development of population pharmacokinetics model of isoniazid in Indonesian patients with tuberculosis
Soedarsono Soedarsono, Rannissa Puspita Jayanti, Ni Made Mertaniasih, et al.
Medicine
|
July 2, 2016
CYP2C19 loss-of-function alleles are not associated with clinical outcome of clopidogrel therapy in patients treated with newer-generation drug-eluting stents
Ik Jun Choi, Yoon-Seok Koh, Mahn-Won Park, et al.
Current Pharmaceutical Design
|
February 26, 2019
10-Phenyltriazoyl Artemisinin is a Novel P-glycoprotein Inhibitor that Suppresses the Overexpression and Function of P-glycoprotein
Dong-Hwan Lee, Md Hasanuzzaman, Daeho Kwon, et al.
Plos One
|
June 6, 2013
Pharmacogenetic study of deferasirox, an iron chelating agent
Ji Won Lee, Hyoung Jin Kang, Ji-Yeob Choi, et al.
Tuberculosis (Edinburgh, Scotland)
|
July 30, 2025
Population pharmacokinetics of levofloxacin in drug-susceptible and drug-resistant tuberculosis patients: Optimal dose suggestion based on renal function
Yong-Soon Cho, Rannissa Puspita Jayanti, Hyun-Kyung Lee, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
March 12, 2008
Identification and characterization of potent CYP2B6 inhibitors in Woohwangcheongsimwon suspension, an herbal preparation used in the treatment and prevention of apoplexy in Korea and China
Hyunmi Kim, Kwon-Bok Kim, Hei-Young Ku, et al.
Frontiers in Immunology
|
November 29, 2023
Alterations of lipid-related genes during anti-tuberculosis treatment: insights into host immune responses and potential transcriptional biomarkers
Nguyen Ky Phat, Nguyen Tran Nam Tien, Nguyen Ky Anh, et al.
Page
of 26
Search research articles
Search
Showing results (231-240 of 256) with videos related to
Sort By:
Page
of 26
Clinical Pharmacology and Therapeutics
|
August 4, 2004
Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states
Kyung-Sang Yu, Joo-Youn Cho, In-Jin Jang, et al.
Pharmacogenomics
|
September 26, 2025
CYP2D6 genotyping in a Korean cohort: comparative analysis with Asian, Caucasian, and African populations
Tak Don Kim, Jung-Sook Kwak, Jae-Gook Shin, et al.
Chemico-Biological Interactions
|
March 3, 2023
Systems-level multi-omics characterization provides novel molecular insights into indomethacin toxicity
Nguyen Thi Hai Yen, Jung-Hwa Oh, Nguyen Thi Van Anh, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
|
January 12, 2022
Development of population pharmacokinetics model of isoniazid in Indonesian patients with tuberculosis
Soedarsono Soedarsono, Rannissa Puspita Jayanti, Ni Made Mertaniasih, et al.
Medicine
|
July 2, 2016
CYP2C19 loss-of-function alleles are not associated with clinical outcome of clopidogrel therapy in patients treated with newer-generation drug-eluting stents
Ik Jun Choi, Yoon-Seok Koh, Mahn-Won Park, et al.
Current Pharmaceutical Design
|
February 26, 2019
10-Phenyltriazoyl Artemisinin is a Novel P-glycoprotein Inhibitor that Suppresses the Overexpression and Function of P-glycoprotein
Dong-Hwan Lee, Md Hasanuzzaman, Daeho Kwon, et al.
Plos One
|
June 6, 2013
Pharmacogenetic study of deferasirox, an iron chelating agent
Ji Won Lee, Hyoung Jin Kang, Ji-Yeob Choi, et al.
Tuberculosis (Edinburgh, Scotland)
|
July 30, 2025
Population pharmacokinetics of levofloxacin in drug-susceptible and drug-resistant tuberculosis patients: Optimal dose suggestion based on renal function
Yong-Soon Cho, Rannissa Puspita Jayanti, Hyun-Kyung Lee, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
March 12, 2008
Identification and characterization of potent CYP2B6 inhibitors in Woohwangcheongsimwon suspension, an herbal preparation used in the treatment and prevention of apoplexy in Korea and China
Hyunmi Kim, Kwon-Bok Kim, Hei-Young Ku, et al.
Frontiers in Immunology
|
November 29, 2023
Alterations of lipid-related genes during anti-tuberculosis treatment: insights into host immune responses and potential transcriptional biomarkers
Nguyen Ky Phat, Nguyen Tran Nam Tien, Nguyen Ky Anh, et al.
Page
of 26